Back to mobile site

Form 6-K Veraxa Biotech Holding For: Jun 18

June 18, 2026 5:20 PM EDT

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2026

 

Commission File Number: 333-289108

 

 

 

Veraxa Biotech AG

 

 

 

Talacker 35

8001 Zurich, Switzerland

 

(Address of principal executive office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒          Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

In Vitro Proof-of-Concept for BiTAC-ADC Technology Platform

 

On June 18, 2026, Veraxa Biotech AG (the “Company”) issued a press release announcing the generation of new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform and the Company's attendance at the BIO International Convention 2026 to discuss partnering opportunities.

 

A copy of the press release is attached as Exhibit 99.1 to this current report on Form 6-K and is incorporated by reference herein.

 

EXHIBIT INDEX

 

Exhibit   Description of Exhibit
99.1   Press Release dated June 18, 2026.

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  VERAXA BIOTECH AG
   
Date: June 18, 2026 By: /s/ Christoph Antz
  Name: Christoph Antz
  Title: Chief Executive Officer

 

  By: /s/ Oliver Baumann
  Name: Oliver Baumann
  Title: Chairman of the Board of Directors

 

2

ATTACHMENTS / EXHIBITS

EXHIBIT 99.1



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings